Description
Product Usage Information
Santacruzamate A (CAY10683) is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.19 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 2 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Background
Santacruzamate A (CAY10683) is a cytotoxin isolated from the Panamanian marine cyanobacterium cf. sp., and is a highly selective inhibitor of histone deacetylases (HDACs), specifically HDAC2 (IC = 0.119 nM) and HDAC6 (IC = 434 nM) (1). This small molecule has been shown to induce apoptosis via transcriptional inhibition of HDAC2, resulting in an increase of p21 Waf1/Cip1 and p19INK4d expression when combined with an HDAC1 inhibitor (2). Santacruzamate A (CAY10683) has also demonstrated the ability to attenuate amyloid-β protein (Aβ) fragment (Aβ )-induced toxicity through enhancing endoplasmic reticulum (ER) stress tolerance in mice (3). Additionally, HDAC2 has been recognized as a host immune response to the influenza A virus (IVA) and several other viruses, making HDAC inhibitors important compounds to study in relation to viral diseases (4,5).
Alternate Names
CAY-10683; CAY10683; N-[4-oxo-4-[2-phenylethylamino]butyl]-carbamic acid ethyl ester; Santacruzamate; Santacruzamate A
